PURE Bioscience Reports Fiscal 2023 Second Quarter And Six-Month Financial Results

RANCHO CUCAMONGA, Calif.–(BUSINESS WIRE)–PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2023. Q2: Summary of Results of Operations Net product sales were $396,000 and $415,000 for the fiscal…